Nibrozetone has promising neuroprotective effects in Parkinson's
disease (PD) animal models, according to a study released today at
the International Congress of Parkinson's Disease and Movement
Disorders® in Philadelphia.
PHILADELPHIA, Sept. 27,
2024 /PRNewswire-PRWeb/ -- Nibrozetone has promising
neuroprotective effects in Parkinson's disease (PD) animal models,
according to a study released today at the International Congress
of Parkinson's Disease and Movement Disorders® in Philadelphia.
"It's exciting to see new studies that
repurpose cancer drugs for disease-modifying therapies in
neurodegeneration."
Nibrozetone (RRx-001) is a small-molecule chemoprotective agent
with anti-inflammatory effects under clinical investigation to
treat various diseased tissues, such as tumors. Nibrozetone has an
excellent safety record in ongoing human studies. A direct NLRP3
inflammasome inhibitor, nibrozetone aids in decreasing inflammasome
activation, a neuropathological hallmark of PD.
Bhatt et al. investigated the use of nibrozetone as a
disease-modifying therapy for PD by evaluating its therapeutic
efficacy in several PD animal models. A once-daily dose of
nibrozetone was shown to reduce inflammasome activation, induce
activation of the neuroprotective NRF2 pathway, and improve motor
deficits and dopaminergic degeneration.
"The findings in the abstract seem promising with regards to
targeting NLRP3 in two models of dopaminergic neurodegeneration,"
said Malú G. Tansey, professor of neuroscience at University of Florida. "Specifically, the compound
seems to have high potency with once-a-day dosing. The novelty of
the compound is that it simultaneously inhibits NLRP3 and activates
the antioxidant factor Nrf2, and that dual mechanism of action may
be more effective than each alone. Overall, it's exciting to see
new studies that repurpose cancer drugs for disease-modifying
therapies in neurodegeneration."
Full text of this abstract are available at mdsabstracts.org
(Reference #804).
About the 2024 MDS International Congress of Parkinson's Disease
and Movement Disorders
The MDS International Congress is the premier annual event to
advance the clinical and scientific discipline of Movement
Disorders, including Parkinson's disease. Convening thousands of
leading clinicians, scientists and other health professionals from
around the globe, the International Congress will introduce more
than 1,800 scientific abstracts and provide a forum for education
and collaboration on latest research findings and state-of-the-art
treatment options. Learn more at http://www.mdscongress.org.
About the International Parkinson and Movement Disorder
Society:
(MDS), an international society of more than 11,000 clinicians,
scientists, and other healthcare professionals, is dedicated to
improving patient care through education and research. For more
information about MDS, visit http://www.movementdisorders.org
Media Contact
Shea Higgins, International
Parkinson and Movement Disorder Society, +1 (414) 276-2145,
shiggins@movementdisorders.org, movementdisorders.org
Twitter
View original content to download
multimedia:https://www.prweb.com/releases/anti-inflammatory-drug-shows-potential-as-disease-modifying-therapy-for-parkinsons-disease-302258326.html
SOURCE International Parkinson and Movement Disorder Society